SCHEMBL29967352

SCHEMBL29967352

Cc1ccc2cc(C3=CCN(C(=O)OC(C)(C)C)CC3)ccc2n1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.51
GRM1 Q13255 8/20 0.47
GRM5 P41594 7/20 0.47
LIPC P11150 1/20 0.47
LIPG Q9Y5X9 1/20 0.47
PDK4 Q16654 1/20 0.47
PDE10A Q9Y233 1/20 0.47
CDK7 P50613 1/20 0.46
CDK13 Q14004 1/20 0.46
CDK12 Q9NYV4 1/20 0.46
WNT3A P56704 1/20 0.46
TNK2 Q07912 1/20 0.45
JAK1 P23458 1/20 0.45
SOS1 Q07889 1/20 0.45
TLR7 Q9NYK1 1/20 0.45
CYP11B2 P19099 1/20 0.44
KIT P10721 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23411052 1.00 NAMPT (0.51) NAMPTGRM1GRM5LIPCLIPG
SCHEMBL24165469 0.88 NAMPT (0.50) NAMPTGRM1GRM5LIPCLIPG
SCHEMBL30594963 0.85 LIPC (0.49) NAMPTGRM1GRM5LIPCLIPG
SCHEMBL29125243 0.85 LIPC (0.49) NAMPTGRM1GRM5LIPCLIPG
SCHEMBL25171673 0.84 QDPR (0.47) SOS1
SCHEMBL7396863 0.83 NAMPT (0.61) NAMPTGRM1GRM5PDK4PDE10A
SCHEMBL16149998 0.82 NAMPT (0.54) NAMPTGRM1GRM5LIPCLIPG
SCHEMBL21980137 0.82 NAMPT (0.50) NAMPTGRM1GRM5LIPCLIPG
SCHEMBL29733135 0.82 NAMPT (0.50) NAMPTGRM1GRM5LIPCLIPG
SCHEMBL12523749 0.82 NAMPT (0.53) NAMPTGRM1GRM5PDK4CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 CN disclosed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 CN disclosed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA NAMPT 3459/4885GRM1 2125/4885GRM5 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.